UROTHELIAL CARCINOMA

This early-stage study tests a new drug called PF-08046876 in people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. The drug is designed to stick to cancer cells and kill them directly. The main goals are to check safety, find the best dose, an…

This study tests whether giving two drugs—enfortumab vedotin and pembrolizumab—before bladder cancer surgery can eliminate cancer in the lymph nodes and shrink tumors. About 23 adults with advanced bladder cancer that has spread to lymph nodes will receive the combination before …

This study tests two experimental drugs, SI-B003 alone or combined with BL-B01D1, in people with advanced bladder cancer or other solid tumors that have not responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow disease progression. About 52…

This study tests a new drug called GI-101, either alone or with pembrolizumab or lenvatinib, in people with advanced solid tumors (cancers that have spread). The goal is to see if it is safe and works against the cancer. About 317 adults with certain cancers like lung, kidney, or…

This study tests a new version of a cancer drug called UGN-104, given directly into the upper urinary tract, for people with low-grade upper tract urothelial cancer. The goal is to see if it can completely eliminate visible tumors and keep the cancer from coming back. About 70 ad…

This study tests a new drug, BMS-986340, alone or with other cancer treatments in people with advanced solid tumors that have not responded to standard therapy. The main goal is to find safe doses and check for side effects. About 949 adults with various cancers like lung, breast…

This study looks at whether combining radiation and immunotherapy works better than standard chemotherapy for people with high-risk upper urinary tract cancer. The goal is to prevent the cancer from coming back after surgery. About 178 adults with certain high-risk features will …

This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 100 adults with canc…

This study tests if the drug enfortumab vedotin can shrink or eliminate high-grade urothelial carcinoma in the upper urinary tract before standard surgery. It is for 24 people who cannot or choose not to take the chemotherapy drug cisplatin. The main goal is to see if the drug ca…

This study tests a drug called disitamab vedotin, given alone or with pembrolizumab, in people with advanced bladder cancer that has spread and cannot be removed by surgery. The cancer must have a protein called HER2 on its cells. The goal is to see if the treatment shrinks tumor…

This study is for people with a type of bladder cancer that hasn't spread into the muscle. It tests a drug called durvalumab, either alone or with other treatments like BCG, radiation, or chemotherapy. The goal is to find safe doses and see how well these combinations work at mak…

This early-stage trial tests a new oral drug, DCC-2812, in about 60 people with advanced kidney, bladder, or prostate cancer that has spread or stopped responding to standard treatments. The main goals are to check safety and find the right dose, while also watching for any tumor…

This study tests a new medicine, PF-08634404, for adults with advanced bladder cancer that has spread. Some participants get the drug alone, others get it with another cancer drug. The goal is to see if the treatment is safe and shrinks tumors. About 132 people will take part.

This study tests whether a combination of two drugs, Talazoparib and Avelumab, can help keep advanced urothelial (bladder) cancer from growing after initial chemotherapy. About 50 adults with cancer that has spread will receive this maintenance therapy. The goal is to see if it d…

This program provides access to an experimental treatment called cretostimogene for people with a type of bladder cancer that has not responded to standard BCG therapy. It is for patients with non-muscle invasive bladder cancer, specifically carcinoma in situ with or without high…

This study tests an experimental oral drug called NEO212 in people with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control the disease. About 134 adults will take part across t…

This early-stage trial tests a new treatment made from donor immune cells (CAR-NK cells) designed to attack two targets on bladder cancer cells. It is for adults with advanced bladder cancer that has not responded to standard therapies. The main goals are to check safety and see …

This study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. About 27 adults will take part in this …

This study is for people with advanced bladder cancer that has spread. After 24 weeks of two powerful drugs (pembrolizumab and enfortumab vedotin), participants whose cancer is controlled may switch to just pembrolizumab alone. The goal is to see if this lighter treatment keeps t…

This study is testing a new drug, enzelkitug, for people with advanced solid tumors that have spread or cannot be removed by surgery. The trial includes many cancer types like lung, head and neck, melanoma, breast, and others. The main goal is to check the drug's safety and find …

This study tests whether a combination of two drugs (sacituzumab govitecan and nivolumab) given after surgery can keep bladder cancer from returning in patients at high risk. About 23 adults who have had their bladder or part of their urinary tract removed will receive the treatm…

This early-stage trial tests a new drug, GEN1106, in about 103 people with solid tumors that have not responded to standard treatments. The study has three parts: first, finding a safe dose; then refining that dose; and finally, checking how well the drug works in a specific canc…

This study tests a combination of two drugs (9MW2821 and Toripalimab) given before and after surgery for people with a type of bladder cancer called urothelial cancer. The goal is to see if this treatment can eliminate cancer cells or shrink tumors enough to improve outcomes. Abo…

This early-phase study tests a new drug called AVA6000, a chemotherapy that is designed to activate only inside tumors, potentially reducing side effects. It is for people with advanced solid tumors (like breast, ovarian, or salivary gland cancer) that have not responded to stand…

This study tests a combination of two targeted drugs (trastuzumab and serplulimab) plus chemotherapy in 20 adults with advanced bile duct or bladder cancers that have stopped responding to standard treatments. The goal is to see if this triple therapy can shrink tumors and improv…

This early-phase study tests the safety of a new drug, BMS-986504, when given with standard cancer treatments. It is for people with advanced mesothelioma, stomach/esophageal cancer, or bladder cancer that has a specific genetic change (MTAP deletion). The goal is to find the bes…

This early-phase study tests an experimental drug called BL-M07D1 in 280 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug is safe and can shrink tumors in cancers like breast, lung, stomach, and ovarian cancer. Participants must have tr…

This study looks at whether placing a small tube (stent) in the ureter after bladder removal surgery reduces the risk of urinary tract infections. About 70 adults with bladder or pelvic cancer will be randomly assigned to receive a stent or not. Researchers will track infections …

This early-phase study tests a new experimental drug (LB-LR1109) in people with advanced solid tumors like lung, kidney, or skin cancer that no longer respond to standard treatments. The study has two parts: first, the drug is given alone to find the safest dose; second, it is co…

This study is for people with advanced bladder cancer that has stopped responding to standard immunotherapy. It tests new drug combinations, with or without the drug pembrolizumab, to see if they can shrink tumors or slow the disease. About 48 adults will take part, and the main …

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 participants wi…

This study tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has not responded to prior treatments. About 508 adults will be randomly assigned to receive either the new drug or a doctor-chosen chemotherapy. The goal is to …

This early-stage study tests a new drug, QXL138AM, for safety in about 100 people with advanced solid tumors (like ovarian, pancreatic, lung, or breast cancer) or multiple myeloma. Participants must have tried other treatments without success. The study will find the right dose a…

This study tests a new drug (trastuzumab rezetecan) alone or with an immunotherapy (adebrelimab) in 96 adults with advanced or metastatic bladder cancer that has the HER2 protein. The goal is to see if the treatment shrinks tumors and how long it keeps the cancer from growing. Pa…

This study tests a new drug called ALE.P03 in adults with advanced cancers (cervical, lung, colorectal, bile duct, or bladder) that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called Claudin-1 found on these tumor…

This study tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein. Participants must have already tried at least one other cancer treatment. The goal is to see if the drug can shrink tumors or stop them from growing. This is not…

This study tests whether a combination of two chemotherapy drugs, gemcitabine and docetaxel, can treat high-risk bladder cancer that did not respond to standard BCG therapy. About 174 adults will receive the drugs directly into the bladder weekly for 6 weeks, then monthly for up …

This study is testing whether routine urine tests every 6 months for 2 years can find bladder cancer at an earlier stage in people at high risk. Participants must be 50 or older with a heavy smoking history or long-term exposure to certain workplace chemicals. The goal is to see …

This study tests a new radioactive tracer called [68Ga]N188 for PET scans to find a protein called nectin-4 in people with urothelial carcinoma, a type of bladder cancer. The goal is to see if this tracer can better detect tumors, especially in patients with advanced or recurring…

This study is testing whether a combination of a blood test and a urine test can detect aggressive muscle-invasive bladder cancer that standard scopes might miss. About 92 people scheduled for bladder removal surgery will provide samples before their operation. If the tests prove…

This study aims to see how well specially trained dogs can detect bladder cancer just by smelling urine samples. About 340 adults scheduled for bladder surgery will provide urine samples for the dogs to sniff. The goal is to measure the dogs' accuracy, which could lead to a new, …

This study is testing whether a urine test that looks for tumor DNA can accurately detect bladder cancer, potentially replacing the need for an invasive cystoscopy. Researchers will collect urine samples from 3,000 people who are already scheduled for a cystoscopy due to blood in…

This study is for people aged 50–75 with Lynch syndrome, a genetic condition that raises the risk of several cancers, including bladder and urinary tract cancers. Researchers want to see if a urine test that looks for tumor DNA can find these cancers early, before symptoms appear…

This study is testing a non-invasive urine test called Cxbladder Triage-Plus to see if it can accurately detect bladder cancer in people who have blood in their urine (microscopic hematuria). Currently, many patients need a cystoscopy, an invasive camera procedure, to check for c…

This study tests whether wearing a compression stocking on one foot during antibody-drug conjugate (ADC) infusions can prevent nerve damage (peripheral neuropathy). About 58 adults with advanced cancers like bladder cancer will take part. Each person will wear a stocking on their…

This study looks at whether giving the cancer drug nivolumab as a shot at home is as good as getting it at the clinic. About 50 adults with various cancers will try both ways to see which they prefer and how it affects their quality of life. The goal is to reduce the time, cost, …

This study is testing whether a personalized home exercise program, delivered through a smartphone app, can improve physical function and recovery in people scheduled for bladder or upper tract cancer surgery. About 128 participants will either receive the exercise program plus s…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if patients prefer home care and if it is safe. Participants will receive their usual cancer drugs either at home or in the clini…

This study looks at two treatment options for people aged 65 and older with advanced bladder cancer who cannot take the chemotherapy drug cisplatin. Researchers want to see which treatment better maintains quality of life and causes fewer side effects. Participants will receive e…

This study looks at how hospitals across the country handle patients who are admitted with blood in their urine (hematuria). Researchers will track over 1,000 patients to see what tests and treatments they receive, how long they stay in the hospital, and their outcomes. The goal …

This study looks at whether removing lymph nodes during surgery for a rare kidney cancer (upper tract urothelial carcinoma) helps prevent the cancer from coming back. About 94 adults will be randomly assigned to have standard surgery alone or with lymph node removal. The main goa…

This study is testing whether an artificial intelligence (AI) tool can help match people with advanced cancer to the right clinical trials. Researchers will enroll up to 50,000 participants to see if the AI improves trial enrollment rates and patient outcomes. The goal is to make…

This study looks at 300 women aged 50 and older who have blood in their urine along with a bladder infection. Researchers want to see if these women need the full set of cancer tests (like a camera in the bladder and CT scans) or if they can safely skip them. The goal is to find …

This study looks at how a drug called enfortumab vedotin affects the nerves of people with advanced bladder cancer that has spread. Researchers will measure nerve function with simple tests before and during treatment. The goal is to better understand and possibly prevent nerve d…

This study looks at how kidney and bladder cancers use nutrients like sugar and fat to grow. About 600 adults having surgery or a biopsy will receive a special nutrient tracer through an IV. Blood and tissue samples are then analyzed to see how the cancer uses these fuels. Partic…

This study aims to collect and store blood, urine, stool, and tumor samples from 1,000 adults with suspected or diagnosed urothelial carcinoma (a type of bladder cancer). The samples will be kept in a secure lab for future research to better understand the disease. No new treatme…

This study is a registry that collects information from about 1,930 people with advanced kidney or bladder cancer in Germany. Researchers will track what treatments patients actually receive, how their disease responds, and their quality of life over time. The goal is to understa…

This study is for people with certain advanced cancers (like lung, head and neck, or esophageal cancer) who are already scheduled to receive immunotherapy (PD-1/PD-L1 inhibitors). Researchers want to see if adding radiation therapy improves outcomes and, more importantly, if chan…